Fayez Sarofim & Co. cut its stake in shares of Celgene Co. (NASDAQ:CELG) by 3.0% during the 3rd quarter, HoldingsChannel reports. The fund owned 611,672 shares of the biopharmaceutical company’s stock after selling 18,998 shares during the period. Fayez Sarofim & Co.’s holdings in Celgene were worth $89,194,000 as of its most recent SEC filing.
A number of other institutional investors also recently added to or reduced their stakes in CELG. Janus Henderson Group PLC raised its position in shares of Celgene by 4,290.5% in the 2nd quarter. Janus Henderson Group PLC now owns 8,408,961 shares of the biopharmaceutical company’s stock valued at $1,092,071,000 after purchasing an additional 8,217,433 shares in the last quarter. BlackRock Inc. raised its position in shares of Celgene by 5.7% in the 2nd quarter. BlackRock Inc. now owns 56,725,342 shares of the biopharmaceutical company’s stock valued at $7,366,919,000 after purchasing an additional 3,084,227 shares in the last quarter. Oaktop Capital Management II L.P. acquired a new position in shares of Celgene in the 2nd quarter valued at approximately $271,605,000. Arrowstreet Capital Limited Partnership raised its position in shares of Celgene by 1,489.2% in the 2nd quarter. Arrowstreet Capital Limited Partnership now owns 1,907,052 shares of the biopharmaceutical company’s stock valued at $247,669,000 after purchasing an additional 1,787,052 shares in the last quarter. Finally, Vanguard Group Inc. raised its position in shares of Celgene by 3.1% in the 2nd quarter. Vanguard Group Inc. now owns 53,527,210 shares of the biopharmaceutical company’s stock valued at $6,951,579,000 after purchasing an additional 1,610,056 shares in the last quarter. 79.85% of the stock is currently owned by hedge funds and other institutional investors.
A number of equities analysts have issued reports on the company. Royal Bank of Canada reaffirmed a “buy” rating and issued a $173.00 target price on shares of Celgene in a research report on Thursday, October 5th. Morgan Stanley lowered Celgene from an “equal weight” rating to an “underweight” rating and set a $120.00 target price on the stock. in a research report on Thursday, October 5th. Robert W. Baird reissued a “buy” rating and set a $162.00 price target on shares of Celgene in a research report on Thursday, September 21st. Cantor Fitzgerald reissued a “buy” rating and set a $162.00 price target on shares of Celgene in a research report on Tuesday, September 26th. Finally, Vetr raised Celgene from a “hold” rating to a “buy” rating and set a $146.58 price target on the stock in a research report on Friday, October 6th. One investment analyst has rated the stock with a sell rating, fourteen have given a hold rating and nineteen have issued a buy rating to the stock. The stock currently has a consensus rating of “Buy” and an average price target of $131.18.
Celgene Co. (NASDAQ:CELG) opened at $104.82 on Wednesday. The company has a market capitalization of $83,455.59, a price-to-earnings ratio of 24.90, a P/E/G ratio of 0.68 and a beta of 1.77. The company has a debt-to-equity ratio of 1.31, a quick ratio of 3.52 and a current ratio of 3.65. Celgene Co. has a 52 week low of $94.55 and a 52 week high of $147.17.
Celgene (NASDAQ:CELG) last issued its quarterly earnings data on Thursday, October 26th. The biopharmaceutical company reported $1.91 EPS for the quarter, topping the Zacks’ consensus estimate of $1.87 by $0.04. Celgene had a return on equity of 63.80% and a net margin of 27.36%. The firm had revenue of $3.29 billion during the quarter, compared to the consensus estimate of $3.42 billion. During the same period in the prior year, the business earned $1.58 EPS. The firm’s revenue was up 10.2% on a year-over-year basis. analysts anticipate that Celgene Co. will post 6.69 earnings per share for the current year.
COPYRIGHT VIOLATION NOTICE: This story was originally reported by Transcript Daily and is the sole property of of Transcript Daily. If you are reading this story on another publication, it was stolen and republished in violation of United States & international trademark & copyright laws. The correct version of this story can be accessed at https://transcriptdaily.com/2018/01/17/fayez-sarofim-co-sells-18998-shares-of-celgene-co-celg.html.
Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.
Want to see what other hedge funds are holding CELG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Celgene Co. (NASDAQ:CELG).
Receive News & Ratings for Celgene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene and related companies with MarketBeat.com's FREE daily email newsletter.